Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)

Predictors of Mechanical Ventilation in Guillain–Barré Syndrome with Axonal Subtypes

“…Most published papers regarding diagnosis, prognosis, and treatment of patients with GBS derive from either exclusive or predominant cohorts with AIDP, 2,16,30-32 which might be a limitation when extrapolating results in Asian or Latin American populations regarding treatment response and outcomes. [9][10][11][12][13][14][15][34][35][36] Therefore, there is an urgent need to study whether treatment responses and outcomes apply in the same way as it has been described in patients with the classical AIDP. In our present report, we demonstrate that the clinical presentation is of utmost importance when classifying the risk of respiratory failure in GBS patients with a high frequency of AMAN and AMSAN variants.…”

“…This frequency appears to be more comparable to what was observed in non-Western populations such as Central and South America, and Asian countries, in that axonal subtypes account for 30-56% of cases. [9][10][11][12][13][14][15][34][35][36] Despite not being an independent predictor when including in the multivariate model to published grading scales, the axonal variants had more cases of respiratory failure than the classical GBS, AIDP. This finding contrasts with other reports that patients with AIDP needed IMV significantly more frequently than those without AMAN/AMSAN.…”

Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series

“…IVIG is used as an alternative to IgG in patients with immunodeficiency or those who are unable to produce antibodies. In these patients, IVIG leads to inactive immunity and provides adequate antibody levels to prevent infections (Kile et al, 2020;Shalman et al, 2020).…”

Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?

“…We read with great interest the case report by Shalman and colleagues who reported a 21-year-old male patient with Guillain-Barré syndrome (GBS) responsive to a second course of intravenous immunoglobulin (IVIg) treatments and the responsiveness was associated with the albumin level in serum [1]. This case report is interesting, and its finding is consistent with a former clinical trial suggesting that serum albumin could be a potential biomarker to monitor the treatment responses to IVIg among patients with GBS [2].…”

“…As CIM may occur independently of or cocomitant with CIP, serum creatine kinase may be of help for the exclusion of CIM. Indeed, the patient contracted pneumonia during his stay in the intensive care unit and required antibiotic treatment [1]. Critical…”